Taro To Expand ElixSure Line, Posts 49% Sales Gain In 2003
This article was originally published in The Tan Sheet
Executive Summary
Taro Pharmaceutical Industries will expand its ElixSure product line late in the second quarter with Children's ElixSure IB (ibuprofen) Oral Suspension
You may also be interested in...
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly
Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly